Matthew Metzger

Company: Oxford BioTherapeutics

Job title: Program, Alliance & Business Development Manager

Seminars:

Supercharging Mass Spectrometry Techniques to Identify ADC Targets Across Tumor & Healthy Cell Populations 10:45 am

Leveraging multiple key elements to indicate target selection, including prevalence, individual patient marker abundance, and target copy number Maximizing the chance of successful identification via thorough novel target validation steps to fully grasp the data collected Generating in-depth data to analyze the future clinical efficacy and toxicity risk to be expected with a prospective targetRead more

day: Conference Day Two